Eli Lilly and Company Company Profile (NYSE:LLY)

About Eli Lilly and Company (NYSE:LLY)

Eli Lilly and Company logoEli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Company's Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company's human pharmaceutical products include endocrinology products, neuroscience products, oncology products, immunology products and cardiovascular products. The Company's animal health products segment includes products for food animals and products for companion animals. As of December 31, 2016, the Company manufactured and distributed its products through facilities in the United States, Puerto Rico and 14 other countries.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals - NEC
  • Sub-Industry: Pharmaceuticals
  • Symbol: NYSE:LLY
  • CUSIP: 53245710
  • Web: www.lilly.com
Capitalization:
  • Market Cap: $87.72 billion
  • Outstanding Shares: 1,056,300,000
Average Prices:
  • 50 Day Moving Avg: $80.12
  • 200 Day Moving Avg: $79.31
  • 52 Week Range: $64.18 - $86.72
P/E:
  • Trailing P/E Ratio: 40.15
  • Foreward P/E Ratio: 18.96
  • P/E Growth: 1.60
Sales & Book Value:
  • Annual Revenue: $21.59 billion
  • Price / Sales: 4.06
  • Book Value: $13.28 per share
  • Price / Book: 6.25
Dividend:
  • Annual Dividend: $2.08
  • Dividend Yield: 2.5%
Profitability:
  • EBIDTA: $5.64 billion
  • Net Margins: 10.13%
  • Return on Equity: 26.64%
  • Return on Assets: 10.35%
Debt:
  • Debt-to-Equity Ratio: 0.54%
  • Current Ratio: 1.24%
  • Quick Ratio: 0.86%
Misc:
  • Average Volume: 3.83 million shs.
  • Beta: 0.36
  • Short Ratio: 2.62
 

Frequently Asked Questions for Eli Lilly and Company (NYSE:LLY)

What is Eli Lilly and Company's stock symbol?

Eli Lilly and Company trades on the New York Stock Exchange (NYSE) under the ticker symbol "LLY."

How often does Eli Lilly and Company pay dividends? What is the dividend yield for Eli Lilly and Company?

Eli Lilly and Company declared a quarterly dividend on Monday, June 19th. Stockholders of record on Tuesday, August 15th will be given a dividend of $0.52 per share on Friday, September 8th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.50%. The ex-dividend date is Friday, August 11th. View Eli Lilly and Company's Dividend History.

How were Eli Lilly and Company's earnings last quarter?

Eli Lilly and Company (NYSE:LLY) issued its earnings results on Tuesday, April, 25th. The company reported $0.98 earnings per share for the quarter, topping the consensus estimate of $0.96 by $0.02. The firm had revenue of $5.23 billion for the quarter, compared to analyst estimates of $5.22 billion. Eli Lilly and Company had a net margin of 10.13% and a return on equity of 26.64%. The business's quarterly revenue was up 7.5% on a year-over-year basis. During the same period in the prior year, the company posted $0.83 earnings per share. View Eli Lilly and Company's Earnings History.

When will Eli Lilly and Company make its next earnings announcement?

Eli Lilly and Company is scheduled to release their next quarterly earnings announcement on Tuesday, July, 25th 2017. View Earnings Estimates for Eli Lilly and Company.

What guidance has Eli Lilly and Company issued on next quarter's earnings?

Eli Lilly and Company updated its FY17 earnings guidance on Tuesday, April, 25th. The company provided EPS guidance of $4.05-4.15 for the period, compared to the Thomson Reuters consensus estimate of $4.10. The company issued revenue guidance of $21.8-22.3 billion, compared to the consensus revenue estimate of $22.10 billion.

Where is Eli Lilly and Company's stock going? Where will Eli Lilly and Company's stock price be in 2017?

16 brokerages have issued twelve-month price targets for Eli Lilly and Company's stock. Their predictions range from $73.00 to $100.00. On average, they expect Eli Lilly and Company's stock price to reach $88.29 in the next year. View Analyst Ratings for Eli Lilly and Company.

Who are some of Eli Lilly and Company's key competitors?

Who are Eli Lilly and Company's key executives?

Eli Lilly and Company's management team includes the folowing people:

  • David A. Ricks, Chairman of the Board, President, Chief Executive Officer
  • Derica W. Rice, Chief Financial Officer, Executive Vice President - Global Services
  • Jan M. Lundberg Ph.D., Executive Vice President - Science and Technology, President - Lilly Research Laboratories
  • Melissa Stapleton Barnes, Senior Vice President - Enterprise Risk Management and Chief Ethics and Compliance Officer
  • Michael J. Harrington, Senior Vice President, General Counsel
  • Stephen F. Fry, Senior Vice President - Human Resources and Diversity
  • Enrique A. Conterno, Senior Vice President and President - Lilly Diabetes and President - Lilly USA
  • Susan Mahony Ph.D., Senior Vice President and President - Lilly Oncology
  • Barton R. Peterson, Senior Vice President - Corporate Affairs and Communications
  • Leigh Ann Pusey, Senior Vice President - Corporate Affairs and Communications

Who owns Eli Lilly and Company stock?

Eli Lilly and Company's stock is owned by a number of of institutional and retail investors. Top institutional investors include Lilly Endowment Inc. (11.87%), Vanguard Group Inc. (6.49%), BlackRock Inc. (5.89%), Primecap Management Co. CA (5.41%), Wellington Management Group LLP (5.36%) and State Street Corp (4.01%). Company insiders that own Eli Lilly and Company stock include Alfonso G Zulueta, David A Ricks, Derica W Rice, Donald A Zakrowski, Enrique A Conterno, Jackson P Tai, Lilly Endowment Inc, Maria A Crowe, Melissa S Barnes, Michael J Harrington, R David Hoover, Stephen F Fry and Susan Mahony. View Institutional Ownership Trends for Eli Lilly and Company.

Who sold Eli Lilly and Company stock? Who is selling Eli Lilly and Company stock?

Eli Lilly and Company's stock was sold by a variety of institutional investors in the last quarter, including APG Asset Management N.V., Massachusetts Financial Services Co. MA, Lilly Endowment Inc., Bank of New York Mellon Corp, Causeway Capital Management LLC, First American Bank, Primecap Management Co. CA and TIAA CREF Investment Management LLC. Company insiders that have sold Eli Lilly and Company stock in the last year include Alfonso G Zulueta, Derica W Rice, Donald A Zakrowski, Enrique A Conterno, Lilly Endowment Inc, Maria A Crowe, Melissa S Barnes, Michael J Harrington and Susan Mahony. View Insider Buying and Selling for Eli Lilly and Company.

Who bought Eli Lilly and Company stock? Who is buying Eli Lilly and Company stock?

Eli Lilly and Company's stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Beutel Goodman & Co Ltd., Vanguard Group Inc., Winslow Capital Management LLC, Renaissance Technologies LLC, Alliancebernstein L.P., Swiss National Bank and Teacher Retirement System of Texas. Company insiders that have bought Eli Lilly and Company stock in the last two years include Jackson P Tai and R David Hoover. View Insider Buying and Selling for Eli Lilly and Company.

How do I buy Eli Lilly and Company stock?

Shares of Eli Lilly and Company can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Eli Lilly and Company's stock price today?

One share of Eli Lilly and Company stock can currently be purchased for approximately $83.04.


MarketBeat Community Rating for Eli Lilly and Company (NYSE LLY)
Community Ranking:  2.9 out of 5 ( )
Outperform Votes:  604 (Vote Outperform)
Underperform Votes:  438 (Vote Underperform)
Total Votes:  1,042
MarketBeat's community ratings are surveys of what our community members think about Eli Lilly and Company and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Eli Lilly and Company (NYSE:LLY) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 4 Hold Ratings, 11 Buy Ratings
Consensus Rating:Buy (Score: 2.63)
Consensus Price Target: $88.29 (6.32% upside)

Analysts' Ratings History for Eli Lilly and Company (NYSE:LLY)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/22/2017Jefferies Group LLCReiterated RatingBuy$93.00LowView Rating Details
5/21/2017Sanford C. BernsteinReiterated RatingOutperform$88.00MediumView Rating Details
5/16/2017Goldman Sachs Group, Inc. (The)Reiterated RatingConviction-Buy -> Buy$92.00HighView Rating Details
4/29/2017BMO Capital MarketsReiterated RatingUnderperform$71.00 -> $73.00LowView Rating Details
4/27/2017ArgusDowngradeBuy -> Hold$64.18 -> $81.00LowView Rating Details
4/19/2017Citigroup Inc.Boost Price TargetBuy$92.00 -> $100.00LowView Rating Details
4/19/2017Credit Suisse GroupReiterated RatingOutperform$87.00LowView Rating Details
4/17/2017Piper Jaffray CompaniesReiterated RatingBuy$100.00MediumView Rating Details
4/17/2017Cowen and CompanyBoost Price TargetOutperform$85.00 -> $95.00MediumView Rating Details
4/17/2017Morgan StanleyDowngradeOverweight -> Equal Weight$82.00HighView Rating Details
4/7/2017Barclays PLCBoost Price TargetOverweight$85.00 -> $90.00LowView Rating Details
3/20/2017Leerink SwannReiterated RatingOutperformLowView Rating Details
11/26/2016J P Morgan Chase & CoReiterated RatingOverweightN/AView Rating Details
11/25/2016Atlantic SecuritiesDowngradeOverweight -> NeutralN/AView Rating Details
10/27/2016Societe GeneraleReiterated RatingHold$78.00N/AView Rating Details
9/20/2016Deutsche Bank AGReiterated RatingBuyN/AView Rating Details
6/15/2016SunTrust Banks, Inc.Reiterated RatingBuyN/AView Rating Details
2/4/2016Berenberg BankBoost Price TargetBuy$105.00 -> $106.00N/AView Rating Details
12/22/2015Bank of America CorporationReiterated RatingBuy$104.00 -> $108.00N/AView Rating Details
(Data available from 6/27/2015 forward)

Earnings

Earnings History for Eli Lilly and Company (NYSE:LLY)
Earnings by Quarter for Eli Lilly and Company (NYSE:LLY)
Earnings History by Quarter for Eli Lilly and Company (NYSE LLY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/25/2017        
4/25/2017Q1 17$0.96$0.98$5.22 billion$5.23 billionViewN/AView Earnings Details
1/31/2017Q416$0.98$0.95$5.54 billion$5.76 billionViewN/AView Earnings Details
10/25/2016Q316$0.96$0.88$4.23 billion$5.19 billionViewListenView Earnings Details
7/26/2016Q216$0.86$0.86$5.14 billion$5.40 billionViewListenView Earnings Details
4/26/2016Q116$0.85$0.83$4.82 billion$4.87 billionViewListenView Earnings Details
1/28/2016Q415$0.78$0.78$5.33 billion$5.38 billionViewListenView Earnings Details
10/22/2015Q315$0.76$0.89$4.99 billion$4.96 billionViewListenView Earnings Details
7/23/2015Q215$0.74$0.90$4.89 billion$4.98 billionViewListenView Earnings Details
4/23/2015Q115$0.76$0.87$4.62 billion$4.64 billionViewN/AView Earnings Details
1/30/2015Q414$0.74$0.75$5.21 billion$5.12 billionViewN/AView Earnings Details
10/23/2014Q314$0.66$0.66$4.83 billion$4.88 billionViewListenView Earnings Details
7/24/2014Q214$0.66$0.68$4.88 billion$4.94 billionViewN/AView Earnings Details
4/24/2014Q114$0.70$0.70$4.78 billion$4.68 billionViewN/AView Earnings Details
1/30/2014Q413$0.72$0.74$5.46 billion$5.81 billionViewListenView Earnings Details
10/23/2013Q313$1.04$1.11$5.76 billion$5.77 billionViewN/AView Earnings Details
7/24/2013Q2 2013$1.01$1.16$5.82 billion$5.93 billionViewN/AView Earnings Details
4/24/2013Q1 2013$1.05$1.14$5.66 billion$5.60 billionViewN/AView Earnings Details
1/29/2013Q4 2012$0.82$0.85$5.78 billion$5.96 billionViewN/AView Earnings Details
10/24/2012$0.82$0.79ViewN/AView Earnings Details
7/25/2012$0.76$0.83ViewN/AView Earnings Details
4/25/2012$0.80$0.92ViewN/AView Earnings Details
1/31/2012$0.80$0.87ViewN/AView Earnings Details
10/20/2011$1.12$1.13ViewN/AView Earnings Details
7/21/2011$1.18$1.18ViewN/AView Earnings Details
4/18/2011$1.16$1.24ViewN/AView Earnings Details
1/27/2011$1.10$1.11ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Eli Lilly and Company (NYSE:LLY)
2017 EPS Consensus Estimate: $4.14
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.98$0.98$0.98
Q2 20172$1.06$1.07$1.07
Q3 20172$1.02$1.04$1.03
Q4 20172$1.05$1.07$1.06
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for Eli Lilly and Company (NYSE:LLY)
Next Dividend:9/8/2017
Annual Dividend:$2.08
Dividend Yield:2.50%
Dividend Growth:1.30% (3 Year Average)
Payout Ratio:100.48% (Trailing 12 Months of Earnings)
50.49% (Based on This Year's Estimates)
47.49% (Based on Next Year's Estimates)
Track Record:2 Years of Consecutive Dividend Growth
Dividend Payments by Quarter for Eli Lilly and Company (NYSE:LLY)

Dividend History by Quarter for Eli Lilly and Company (NYSE LLY)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/19/2017quarterly$0.522.51%8/11/20178/15/20179/8/2017
5/1/2017quarterly$0.522.55%5/11/20175/15/20176/9/2017
12/13/2016quarterly$0.523.03%2/13/20172/15/20173/10/2017
10/17/2016quarterly$0.512.59%11/10/201611/15/201612/9/2016
6/20/2016quarterly$0.512.81%8/11/20168/15/20169/9/2016
5/2/2016quarterly$0.512.68%5/11/20165/13/20166/10/2016
12/8/2015quarterly$0.512.43%2/10/20162/12/20163/10/2016
10/19/2015quarterly$0.502.57%11/10/201511/13/201512/10/2015
6/15/2015quarterly$0.502.42%8/12/20158/14/20159/10/2015
5/4/2015quarterly$0.502.78%5/14/20155/18/20156/10/2015
12/15/2014quarterly$0.502.89%2/11/20152/13/20153/10/2015
10/20/2014quarterly$0.493.03%11/12/201411/14/201412/10/2014
6/16/2014quarterly$0.493.31%8/13/20148/15/20149/10/2014
5/5/2014quarterly$0.493.35%5/13/20145/15/20146/10/2014
12/16/2013quarterly$0.493.98%2/12/20142/14/20143/10/2014
10/21/2013quarterly$0.493.91%11/13/201311/15/201312/10/2013
6/18/2013quarterly$0.493.82%8/13/20138/15/20139/10/2013
5/6/2013quarterly$0.493.62%5/14/20135/16/20136/10/2013
12/17/2012quarterly$0.493.96%2/13/20132/15/20133/8/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Eli Lilly and Company (NYSE:LLY)
Insider Ownership Percentage: 0.20%
Institutional Ownership Percentage: 75.49%
Insider Trades by Quarter for Eli Lilly and Company (NYSE:LLY)
Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)
Insider Trades by Quarter for Eli Lilly and Company (NYSE:LLY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/22/2017Lilly Endowment IncMajor ShareholderSell210,000$84.43$17,730,300.00View SEC Filing  
6/20/2017Lilly Endowment IncMajor ShareholderSell215,000$83.05$17,855,750.00View SEC Filing  
6/12/2017Melissa S BarnesInsiderSell1,900$80.78$153,482.00View SEC Filing  
6/9/2017Michael J HarringtonVPSell22,833$79.97$1,825,955.01View SEC Filing  
5/4/2017Enrique A ConternoSVPSell25,000$82.76$2,069,000.00View SEC Filing  
3/30/2017Lilly Endowment IncMajor ShareholderSell210,000$84.67$17,780,700.00View SEC Filing  
2/17/2017Lilly Endowment IncMajor ShareholderSell230,000$80.27$18,462,100.00View SEC Filing  
2/6/2017Alfonso G ZuluetaSVPSell15,000$77.66$1,164,900.00View SEC Filing  
2/3/2017Derica W RiceEVPSell11,162$77.14$861,036.68View SEC Filing  
2/2/2017Donald A ZakrowskiInsiderSell2,000$77.52$155,040.00View SEC Filing  
2/1/2017Lilly Endowment IncMajor ShareholderSell220,000$77.35$17,017,000.00View SEC Filing  
12/16/2016Lilly Endowment IncMajor ShareholderSell200,000$72.59$14,518,000.00View SEC Filing  
12/16/2016Melissa S BarnesInsiderSell2,093$82.23$172,107.39View SEC Filing  
12/16/2016R David HooverDirectorBuy500$71.85$35,925.00View SEC Filing  
12/16/2016Susan MahonySVPSell20,242$72.65$1,470,581.30View SEC Filing  
10/5/2016Maria A CroweInsiderSell2,248$81.37$182,919.76View SEC Filing  
8/15/2016Jackson P TaiDirectorBuy5,773$80.43$464,322.39View SEC Filing  
8/12/2016Jackson P TaiDirectorBuy2,560$80.42$205,875.20View SEC Filing  
7/29/2016Lilly Endowment IncMajor ShareholderSell205,000$82.94$17,002,700.00View SEC Filing  
7/28/2016Donald A ZakrowskiInsiderSell1,213$83.16$100,873.08View SEC Filing  
7/28/2016Lilly Endowment IncMajor ShareholderSell240,000$82.87$19,888,800.00View SEC Filing  
7/12/2016Lilly Endowment IncMajor ShareholderSell210,000$79.54$16,703,400.00View SEC Filing  
7/7/2016Lilly Endowment IncMajor ShareholderSell225,000$79.14$17,806,500.00View SEC Filing  
6/30/2016Lilly Endowment IncMajor ShareholderSell215,000$78.46$16,868,900.00View SEC Filing  
6/29/2016Lilly Endowment IncMajor ShareholderSell220,000$77.86$17,129,200.00View SEC Filing  
6/10/2016Melissa S BarnesSVPSell992$73.77$73,179.84View SEC Filing  
5/31/2016Lilly Endowment IncMajor ShareholderSell200,000$75.12$15,024,000.00View SEC Filing  
5/12/2016Jackson P TaiDirectorBuy1,080$75.75$81,810.00View SEC Filing  
5/12/2016Lilly Endowment IncMajor ShareholderSell190,000$75.86$14,413,400.00View SEC Filing  
5/2/2016Donald A ZakrowskiCAOSell1,600$75.86$121,376.00View SEC Filing  
4/29/2016Lilly Endowment IncMajor ShareholderSell180,000$75.44$13,579,200.00View SEC Filing  
4/27/2016Alfonso G ZuluetaSVPSell12,000$76.27$915,240.00View SEC Filing  
4/8/2016Lilly Endowment IncMajor ShareholderSell200,000$74.29$14,858,000.00View SEC Filing  
2/5/2016Stephen F FrySVPSell15,230$78.87$1,201,190.10View SEC Filing  
2/3/2016David A. RicksSVPSell5,733$77.66$445,224.78View SEC Filing  
2/3/2016Derica W. RiceCFOSell10,483$77.78$815,367.74View SEC Filing  
2/1/2016Jackson P TaiDirectorBuy3,170$78.62$249,225.40View SEC Filing  
1/29/2016Alfonso G ZuluetaSVPSell5,000$78.75$393,750.00View SEC Filing  
12/21/2015Lilly Endowment IncMajor ShareholderSell205,000$86.00$17,630,000.00View SEC Filing  
12/15/2015Lilly Endowment IncMajor ShareholderSell215,000$85.60$18,404,000.00View SEC Filing  
12/9/2015Enrique A ConternoVPSell25,000$83.88$2,097,000.00View SEC Filing  
12/2/2015Lilly Endowment Incmajor shareholderSell210,000$85.09$17,868,900.00View SEC Filing  
11/20/2015Lilly Endowment Incmajor shareholderSell205,000$84.54$17,330,700.00View SEC Filing  
10/29/2015Lilly Endowment Incmajor shareholderSell200,000$82.28$16,456,000.00View SEC Filing  
10/9/2015Lilly Endowment Incmajor shareholderSell215,000$85.86$18,459,900.00View SEC Filing  
10/5/2015Lilly Endowment Incmajor shareholderSell260,000$86.46$22,479,600.00View SEC Filing  
9/18/2015Lilly Endowment Incmajor shareholderSell250,000$89.04$22,260,000.00View SEC Filing  
6/10/2015Lilly Endowment IncMajor ShareholderSell210,000$82.39$17,301,900.00View SEC Filing  
6/4/2015Lilly Endowment IncMajor ShareholderSell200,000$77.90$15,580,000.00View SEC Filing  
5/29/2015Jeffrey N SimmonsSVPSell20,000$78.08$1,561,600.00View SEC Filing  
5/20/2015Lilly Endowment IncMajor ShareholderSell190,000$73.43$13,951,700.00View SEC Filing  
5/15/2015Lilly Endowment IncMajor ShareholderSell200,000$72.83$14,566,000.00View SEC Filing  
5/8/2015Lilly Endowment IncMajor ShareholderSell195,000$73.28$14,289,600.00View SEC Filing  
5/1/2015Lilly Endowment IncMajor ShareholderSell200,000$73.09$14,618,000.00View SEC Filing  
3/30/2015Lilly Endowment IncMajor ShareholderSell180,000$73.94$13,309,200.00View SEC Filing  
3/23/2015Lilly Endowment IncMajor ShareholderSell190,000$76.97$14,624,300.00View SEC Filing  
3/9/2015Stephen F FrySVPSell4,000$69.27$277,080.00View SEC Filing  
2/4/2015David A RicksSVPSell3,147$69.99$220,258.53View SEC Filing  
2/4/2015Derica W RiceCFOSell5,316$70.00$372,120.00View SEC Filing  
2/4/2015Jan M LundbergEVPSell11,085$70.08$776,836.80View SEC Filing  
2/3/2015Jan M LundbergEVPSell121,711$70.78$8,614,704.58View SEC Filing  
2/2/2015David A RicksSVPSell4,769$71.51$341,031.19View SEC Filing  
2/2/2015Derica W RiceCFOSell10,068$71.84$723,285.12View SEC Filing  
12/4/2014Lilly Endowment IncMajor ShareholderSell190,000$71.92$13,664,800.00View SEC Filing  
12/2/2014Lilly Endowment IncMajor ShareholderSell180,000$70.14$12,625,200.00View SEC Filing  
11/13/2014Lilly Endowment IncMajor ShareholderSell200,000$67.73$13,546,000.00View SEC Filing  
11/5/2014Lilly Endowment IncMajor ShareholderSell180,000$67.00$12,060,000.00View SEC Filing  
11/4/2014Fionnuala M WalshSVPSell15,000$67.00$1,005,000.00View SEC Filing  
11/3/2014Enrique A ConternoVPSell5,000$66.03$330,150.00View SEC Filing  
10/31/2014Fionnuala M WalshSVPSell7,376$66.58$491,094.08View SEC Filing  
10/31/2014Lilly Endowment IncMajor ShareholderSell190,000$66.40$12,616,000.00View SEC Filing  
10/30/2014Lilly Endowment IncMajor ShareholderSell175,000$66.58$11,651,500.00View SEC Filing  
10/24/2014Maria A CroweInsiderSell2,750$65.77$180,867.50View SEC Filing  
10/6/2014Lilly Endowment IncMajor ShareholderSell210,000$65.63$13,782,300.00View SEC Filing  
10/1/2014Enrique A ConternoVPSell5,000$64.86$324,300.00View SEC Filing  
9/30/2014Lilly Endowment IncMajor ShareholderSell200,000$65.07$13,014,000.00View SEC Filing  
9/10/2014Lilly Endowment IncMajor ShareholderSell210,000$64.77$13,601,700.00View SEC Filing  
9/3/2014Lilly Endowment IncMajor ShareholderSell200,000$63.99$12,798,000.00View SEC Filing  
9/2/2014Enrique A ConternoVPSell5,000$63.60$318,000.00View SEC Filing  
7/29/2014Lilly Endowment IncMajor ShareholderSell250,000$63.03$15,757,500.00View SEC Filing  
7/28/2014Susan MahonySVPSell2,065$63.30$130,714.50View SEC Filing  
7/25/2014Enrique A ConternoVPSell10,000$63.79$637,900.00View SEC Filing  
7/25/2014Susan MahonySVPSell30,000$63.90$1,917,000.00View SEC Filing  
7/1/2014Lilly Endowment IncMajor ShareholderSell235,000$62.30$14,640,500.00View SEC Filing  
6/25/2014Lilly Endowment IncMajor ShareholderSell245,000$62.68$15,356,600.00View SEC Filing  
6/20/2014Lilly Endowment IncMajor ShareholderSell230,000$61.55$14,156,500.00View SEC Filing  
6/16/2014Lilly Endowment IncMajor ShareholderSell200,000$58.73$11,746,000.00View SEC Filing  
6/5/2014Lilly Endowment IncMajor ShareholderSell190,000$59.53$11,310,700.00View SEC Filing  
5/21/2014Lilly Endowment Incmajor shareholderSell230,000$58.90$13,547,000.00View SEC Filing  
5/12/2014Jackson TaiDirectorBuy17,157$59.19$1,015,522.83View SEC Filing  
5/12/2014Lilly Endowment Incmajor shareholderSell210,000$59.33$12,459,300.00View SEC Filing  
5/6/2014Lilly Endowment Incmajor shareholderSell190,000$58.79$11,170,100.00View SEC Filing  
4/29/2014Lilly Endowment Incmajor shareholderSell200,000$59.43$11,886,000.00View SEC Filing  
4/28/2014Lilly Endowment Incmajor shareholderSell150,000$58.64$8,796,000.00View SEC Filing  
8/15/2013Enrique ConternoVPSell5,000$53.79$268,950.00View SEC Filing  
7/29/2013Jacques TapieroSVPSell7,500$53.74$403,050.00View SEC Filing  
7/15/2013Enrique A ConternoVPSell5,000$51.43$257,150.00View SEC Filing  
6/17/2013Enrique A ConternoVPSell5,000$52.45$262,250.00View SEC Filing  
5/15/2013Enrique A ConternoVPSell5,000$56.15$280,750.00View SEC Filing  
5/10/2013Jeffrey N SimmonsSVPSell10,000$54.49$544,900.00View SEC Filing  
3/26/2013Susan MahonySVPSell5,000$56.00$280,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Eli Lilly and Company (NYSE:LLY)
Latest Headlines for Eli Lilly and Company (NYSE:LLY)
Source:
DateHeadline
finance.yahoo.com logoTanezumab Receives FDA Fast Track Designation
finance.yahoo.com - June 27 at 6:27 PM
finance.yahoo.com logoLilly Diabetes Brings an Extra Splash of Summertime Fun and Inspiration to Diabetes Camps with Launch of Annual Camp Care Package Speaker Tour
finance.yahoo.com - June 27 at 6:27 PM
finance.yahoo.com logoPfizer Fueling Growth Of Competitors' Pipelines
finance.yahoo.com - June 27 at 6:27 PM
finance.yahoo.com logo[$$] Merck Cholesterol Drug Could Help Unlock Value
finance.yahoo.com - June 27 at 6:27 PM
finance.yahoo.com logoBetter Buy: Eli Lilly and Co. vs. Merck & Co., Inc.
finance.yahoo.com - June 27 at 6:27 PM
feeds.benzinga.com logoQS/1 Names New President
feeds.benzinga.com - June 27 at 2:55 PM
marketbeat.com logoMerck says new type of cholesterol drug worked in big study
marketbeat.com - June 27 at 11:30 AM
finance.yahoo.com logoETFs with exposure to Eli Lilly & Co. : June 26, 2017
finance.yahoo.com - June 27 at 12:05 AM
americanbankingnews.com logoEli Lilly and Company (LLY) Expected to Announce Quarterly Sales of $5.59 Billion
www.americanbankingnews.com - June 24 at 8:15 AM
streetinsider.com logoEli Lilly & Co. (LLY): Softer Landing Now Anticipated If Worst Case Plays Out - Jefferies - StreetInsider.com
www.streetinsider.com - June 23 at 6:44 PM
americanbankingnews.com logoEli Lilly and Co (LLY) Major Shareholder Sells $17,730,300.00 in Stock
www.americanbankingnews.com - June 23 at 1:35 PM
americanbankingnews.com logoJefferies Group LLC Reaffirms "Buy" Rating for Eli Lilly and Company (LLY)
www.americanbankingnews.com - June 22 at 9:52 PM
americanbankingnews.com logo$1.03 EPS Expected for Eli Lilly and Company (LLY) This Quarter
www.americanbankingnews.com - June 22 at 8:38 PM
americanbankingnews.com logoEli Lilly and Company (LLY) Forecasted to Post FY2020 Earnings of $5.85 Per Share
www.americanbankingnews.com - June 22 at 2:54 PM
americanbankingnews.com logoCritical Comparison: Assembly Biosciences (ASMB) vs. Eli Lilly and Company (LLY)
www.americanbankingnews.com - June 22 at 9:06 AM
prnewswire.com logoEli Lilly and Company Unveils Expanded Biotechnology Center in San Diego - PR Newswire (press release)
www.prnewswire.com - June 21 at 7:22 PM
finance.yahoo.com logoEli Lilly and Company Unveils Expanded Biotechnology Center in San Diego
finance.yahoo.com - June 21 at 7:22 PM
americanbankingnews.com logoInsider Selling: Eli Lilly and Company (LLY) Major Shareholder Sells 215,000 Shares of Stock
www.americanbankingnews.com - June 21 at 4:35 PM
seekingalpha.com logoEli Lilly and Company (LLY) Updates On Pain Portfolio - Slideshow
seekingalpha.com - June 20 at 7:14 PM
americanbankingnews.com logoEli Lilly and Company (LLY) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - June 20 at 7:02 PM
finance.yahoo.com logoLilly Declares Third-Quarter 2017 Dividend
finance.yahoo.com - June 19 at 5:19 PM
americanbankingnews.com logoEli Lilly and Company (LLY) Declares $0.52 Quarterly Dividend
www.americanbankingnews.com - June 19 at 1:44 PM
marketwatch.com logoCISCRP Supports Lilly's Hero's Journey Art Project to Honor Clinical Trial Participants
www.marketwatch.com - June 19 at 11:53 AM
finance.yahoo.com logoHow Eli Lilly’s Taltz Performed in Clinical Trials
finance.yahoo.com - June 19 at 11:53 AM
finance.yahoo.com logoLilly and NRAS Launch New Film for RA Awareness Week to Reveal the True Impact of RA
finance.yahoo.com - June 19 at 11:53 AM
finance.yahoo.com logoFDA Approves Eli Lilly’s Humalog Junior KwikPen
finance.yahoo.com - June 19 at 11:53 AM
finance.yahoo.com logoFDA Grants Fast-Track Designation to Tanezumab
finance.yahoo.com - June 19 at 11:53 AM
nasdaq.com logoEli Lilly Reports Results From Extension Period Of SPIRIT-P1 Trial
www.nasdaq.com - June 17 at 5:18 AM
News IconBRIEF-Eli Lilly files supplemental biologics license application with FDA for Taltz
www.businessinsider.com - June 16 at 7:14 PM
finance.yahoo.com logoEULAR 2017: Lilly's Taltz® (ixekizumab) Demonstrated Significant Improvements in Disease Signs and Symptoms at 24 Weeks Among Patients with Active Psoriatic Arthritis Who Had Prior Inadequate Response or Intolerance to TNF Inhibitors
finance.yahoo.com - June 16 at 7:14 PM
finance.yahoo.com logoHealth-care reform should include 'faster' FDA on drug ap...
finance.yahoo.com - June 16 at 7:14 PM
finance.yahoo.com logoETFs with exposure to Eli Lilly & Co. : June 15, 2017
finance.yahoo.com - June 16 at 7:14 PM
finance.yahoo.com logoEli Lilly & Co. – Value Analysis (NYSE:LLY) : June 15, 2017
finance.yahoo.com - June 16 at 7:14 PM
finance.yahoo.com logoEli Lilly and Company: RA Matters Survey Uncovers What Matters Most to Over 5,000 People Living With Rheumatoid Arthritis
finance.yahoo.com - June 16 at 7:14 PM
finance.yahoo.com logoEli Lilly & Co. :LLY-US: Earnings Analysis: Q1, 2017 By the Numbers : June 16, 2017
finance.yahoo.com - June 16 at 7:14 PM
prnewswire.com logoEULAR 2017: Lilly's Taltz® (ixekizumab) Demonstrated Significant Improvements in Disease Signs and Symptoms at ... - PR Newswire (press release)
www.prnewswire.com - June 16 at 7:21 AM
streetinsider.com logoEli Lilly & Co. (LLY) & Incyte Corp. (INCY) Present New Safety & Long-Term Efficacy Data from Baricitinib Clinical ... - StreetInsider.com
www.streetinsider.com - June 16 at 7:21 AM
fool.com logo5 Things You Didn't Know About Eli Lilly and Co - Motley Fool
www.fool.com - June 16 at 7:21 AM
prnewswire.com logoEULAR 2017: Lilly's Taltz® (ixekizumab) Demonstrated No Progression or Minimal Progression of Radiographic ... - PR Newswire (press release)
www.prnewswire.com - June 16 at 7:21 AM
finance.yahoo.com logoEULAR 2017: Lilly's Taltz® (ixekizumab) Demonstrated No Progression or Minimal Progression of Radiographic Disease in Patients with Psoriatic Arthritis Through 52 Weeks
finance.yahoo.com - June 16 at 7:21 AM
cnbc.com logoEli Lilly CEO weighs in on drug costs and health reform
www.cnbc.com - June 15 at 3:44 PM
finance.yahoo.com logoPfizer & Lilly Get Fast Track Designation for Pain Candidate
finance.yahoo.com - June 14 at 9:11 PM
finance.yahoo.com logo[$$] JNJ Diabetes Data Benefit Lilly, Hurt Merck
finance.yahoo.com - June 14 at 9:11 PM
finance.yahoo.com logo5 Things You Didn't Know About Eli Lilly and Co
finance.yahoo.com - June 14 at 9:11 PM
americanbankingnews.com logoEli Lilly and Company (LLY) Rating Increased to Hold at BidaskClub
www.americanbankingnews.com - June 14 at 7:48 PM
News IconBRIEF-Eli Lilly updates on study data on Jardiance
www.businessinsider.com - June 14 at 10:29 AM
finance.yahoo.com logoEli Lilly & Co. breached its 50 day moving average in a Bullish Manner : LLY-US : June 14, 2017
finance.yahoo.com - June 14 at 10:29 AM
streetinsider.com logoLilly to share 31 abstracts, including 27 abstracts detailing safety, efficacy and patient outcomes data for Olumiant and Taltz
www.streetinsider.com - June 13 at 11:15 PM
finance.yahoo.com logoJardiance® (empagliflozin) analysis reinforces established safety profile
finance.yahoo.com - June 13 at 11:15 PM
americanbankingnews.com logoEli Lilly and Company (LLY) Insider Sells $153,482.00 in Stock
www.americanbankingnews.com - June 13 at 8:14 PM

Social

Chart

Eli Lilly and Company (LLY) Chart for Tuesday, June, 27, 2017

This page was last updated on 6/27/2017 by MarketBeat.com Staff